FAP PET/CT for Staging Patients With Breast Cancer

[⁶⁸Ga]Ga-FAP-2286 PET/CT for Staging and Restaging Patients With Newly Diagnosed Primary Breast Cancer: a Phase II Study (FAPILOUS)

This study aims to evaluate the clinical utility of [68Ga]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer. By targeting fibroblast activation protein (FAP), this novel imaging approach may offer improved tumor visualization compared to conventional imaging, which may help improve treatment planning.

Inclusion Criteria:

• Male and females ≥ 18 years
• Biopsy-verified newly diagnosed breast cancer
• Can read and understand Danish
• Capable of providing written and informed consent
• Undergoing a routine [¹⁸F]FDG PET/CT scan as part of the clinical standard diagnostic workup

Exclusion Criteria:

• Pregnant or lactating women
• Not able to participate in the conduct of the scan due to any reason ( e.g., claustrophobia or inability to lie still for entire imaging time)
• Ongoing oncological treatment for another cancer
• History of allergic reactions / hypersensitivity attributed to [⁶⁸Ga]Ga-FAP-2286.